Molecular Partners to Showcase DLL3-Targeting Radio-DARPin MP0712 at Key Cancer Conferences
Event summary
- Molecular Partners will present data on its DLL3-targeting Radio-DARPin candidate MP0712 at three scientific conferences in May 2026.
- Presentations will cover preclinical insights, clinical development, and first-in-human data for MP0712.
- Conferences include the NIH National Cancer Institute SCLC Consortium, PEGS Boston, and Antibody & Engineering Therapeutics.
- MP0712 is a ²¹²Pb-based radiopharmaceutical targeting DLL3 in small cell lung cancer (SCLC).
The big picture
Molecular Partners' presentations highlight the growing interest in targeted alpha therapy for SCLC, a field where DLL3 is emerging as a key biomarker. The company's focus on Radio-DARPins positions it in a niche segment of radiopharmaceuticals, competing with antibody-drug conjugates (ADCs) and other targeted therapies. Success in these presentations could bolster investor confidence in the company's pipeline and strategic direction.
What we're watching
- Clinical Validation
- How early clinical data for MP0712 will position it against competing DLL3-targeting therapies.
- Partnership Dynamics
- Whether the collaboration with Orano Med will accelerate MP0712's development timeline.
- Market Differentiation
- The pace at which Molecular Partners can establish Radio-DARPins as a distinct class of radiopharmaceuticals.
Related topics